Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program , and the “National Natural Science Foundation . Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program , and the “National Natural Science Foundation . Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation. Lihui Wang, PhD, obtained his PhD in Pharmacology from Shenyang Pharmaceutical University in 2006. After that, Dr Wang started his investigation in the same institute, where he was promoted to full professor in 2018. From 2016 spring to 2017 summer, Dr. Wang majors in anti-cancer drug researches and went to Memorial Sloan Kettering Cancer Center in New York as a visiting investigator. Dr. Wang has published more than 20 papers, as first or corresponding author, in international peer reviewed journals, and his research focus is anti-cancer drugs development and chemo-sensitization.

Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program , and the “National Natural Science Foundation . Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program , and the “National Natural Science Foundation . Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation. Lihui Wang, PhD, obtained his PhD in Pharmacology from Shenyang Pharmaceutical University in 2006. After that, Dr Wang started his investigation in the same institute, where he was promoted to full professor in 2018. From 2016 spring to 2017 summer, Dr. Wang majors in anti-cancer drug researches and went to Memorial Sloan Kettering Cancer Center in New York as a visiting investigator. Dr. Wang has published more than 20 papers, as first or corresponding author, in international peer reviewed journals, and his research focus is anti-cancer drugs development and chemo-sensitization.